

Orasure Technologies Inc. (OSUR)

Nasdaq; healthcare; SIC 3841, Surgical & Medical Instruments & Apparatus; CIK 000116463

Orasure Technologies Inc.	
OSUR; healthcare	
Grade	C middle fifth of 371 graded peers percentile 45.9; sampling error 2.5 points; lower is stronger
Rank	171 of 371
Profitability	D percentile 67.3
Solvency	A/B percentile 21.3
Growth and financing	C percentile 51.1
Reliability	0.87 AUC filers with \$120M to \$591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025
Peer failure rate	1.03% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	\$120M to \$591M assets total assets \$403.2M
Standard universe	inside revenue above \$1M and assets above \$10M
Warnings	none active not computable: distress, fortress balance sheet
Inputs computable	8 of 14
Graded from	filings received through Mar 9, 2026 214 days before the rescans; latest periodic filing 10-Q received Aug 7, 2026
Last close	\$3.79 2026-10-08; market equity \$261.4M
Price used in grade	None


C, the tortoise
middle fifth of its sector; letters are fifths of the 371 graded peers

Share price, twelve months to the rescans
split-adjusted close; the letter is fixed at the rescans that set it

Rescans on file: B/C from Feb 21, 2024, A from Mar 21, 2024, B from Mar 21,

Letter at every rescans

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Mar 9, 2026

OTI transforms health through actionable insight and decentralizes diagnostics to connect people to healthcare wherever they are. Our products and services reside under one reporting hierarchy, with commercial and innovation teams, which are part of a single business unit covering multiple product lines. Our business is principally comprised of the development, manufacture, marketing, sale and distribution of (i) diagnostics products, and (ii) sample management solutions. In November 2025, the Company acquired

BioMedomics, Inc. ("BioMedomics"). BioMedomics' SickleSCAN® test is the world's first rapid point-of-care test for sickle cell disease.


The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 67.3						
Gross profitability		12.0%	32.2%	73.6	372	2025-12-31
Return on invested capital		not computable	9.3%			one or more required annual facts are missing
Accruals ratio		(4.5%)	(6.6%)	63.7	811	2025-12-31
Gross margin stability, five years		3.9 pts	2.8 pts	64.5	243	2025-12-31
Solvency, sleeve percentile 21.3						
Twelve-month failure probability		not computable	0.07%			latest liabilities, cash plus short-term investments, book equity, and shares are required
Altman Z double-prime		6.76	(0.31)	14.8	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			one or more required annual facts are missing
Interest coverage		not computable	(4.51x)			latest aligned inputs end 2012-12-31; latest annual assets end 2025-12-31
Current ratio		6.58x	2.96x	27.8	839	2025-12-31
Growth and financing, sleeve percentile 51.1						
Revenue growth, three-year compound		(33.3%)	10.0%	92.5	415	2025-12-31
Free cash flow growth, three-year compound		not computable	10.9%			current FCF must be positive and base FCF must exceed \$100,000 pretax income must exceed the validity floor and imply a 0%-100% tax rate
Reinvestment rate		not computable	37.1%			
Asset growth, three years		(3.2%)	2.1%	59.2	704	2025-12-31
Net share issuance, one year		(7.6%)	2.5%	1.6	634	2026-02-28

Among 371 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
166	Avita Medical, Inc. (RCEL)	44.6	C	short runway
167	Johnson & Johnson (JNJ)	44.9	C	
168	Lensar, Inc. (LNSR)	45.1	C	
169	Integer Holdings Corp. (ITGR)	45.4	C	
170	Zimmer Biomet Holdings, Inc. (ZBH)	45.7	C	
171	Orasure Technologies Inc. (OSUR) <	45.9	C	
172	Pediatrix Medical Group, Inc. (MD)	46.2	C	
173	Enovis Corp. (ENOV)	46.5	C	
174	Align Technology Inc. (ALGN)	46.8	C	
175	ClearPoint Neuro, Inc. (CLPT)	47.0	C	
176	Anika Therapeutics, Inc. (ANIK)	47.3	C	fortress balance sheet

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	11.8%	8.0%	52
Distance from 52-week high	(15.7%)	(31.4%)	72
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	(20.3%)	(1.0%)	22
Book value to price	1.21	0.28	90
Sales to price	0.44	0.31	63
Composite equity issuance, five years	(4.2%)	20.3%	21
Relative strength against the sector, log excess return	(0.10)	(0.14)	52

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	pass
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	\$160.6M
Operating cash flow, four quarters	-\$42.9M
Months of runway	44.9
Days since last periodic filing	63 (10-Q received Aug 7, 2026)
Median daily dollar volume, 63 sessions	\$1.6M

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	\$48.2M	2025-12-31	2026-03-09	10-K	0001116463-26-000016
2	assets	us-gaap:Assets	\$403.2M	2025-12-31	2026-03-09	10-K	0001116463-26-000016
3	net income	us-gaap:NetIncomeLoss	-\$68.7M	2025-12-31	2026-03-09	10-K	0001116463-26-000016
4	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$49.0M	2025-12-31	2026-03-09	10-K	0001116463-26-000016
5	assets	us-gaap:Assets	\$479.7M	2024-12-31	2026-03-09	10-K	0001116463-26-000016
6	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$115.0M	2025-12-31	2026-03-09	10-K	0001116463-26-000016
7	gross profit	us-gaap:GrossProfit	\$79.4M	2024-12-31	2026-03-09	10-K	0001116463-26-000016
8	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$185.8M	2024-12-31	2026-03-09	10-K	0001116463-26-000016
9	gross profit	us-gaap:GrossProfit	\$171.7M	2023-12-31	2026-03-09	10-K	0001116463-26-000016
10	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$405.5M	2023-12-31	2026-03-09	10-K	0001116463-26-000016
11	gross profit	us-gaap:GrossProfit	\$148.4M	2022-12-31	2025-03-07	10-K	0001116463-25-000010
12	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$387.5M	2022-12-31	2025-03-07	10-K	0001116463-25-000010
13	gross profit	us-gaap:GrossProfit	\$117.6M	2021-12-31	2024-03-11	10-K	0001116463-24-000012
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$233.7M	2021-12-31	2024-03-11	10-K	0001116463-24-000012
15	current assets	us-gaap:AssetsCurrent	\$261.9M	2025-12-31	2026-03-09	10-K	0001116463-26-000016
16	current liabilities	us-gaap:LiabilitiesCurrent	\$39.8M	2025-12-31	2026-03-09	10-K	0001116463-26-000016
17	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$172.2M	2025-12-31	2026-03-09	10-K	0001116463-26-000016
18	operating income	us-gaap:OperatingIncomeLoss	-\$72.0M	2025-12-31	2026-03-09	10-K	0001116463-26-000016
19	book equity	us-gaap:StockholdersEquity	\$340.8M	2025-12-31	2026-03-09	10-K	0001116463-26-000016
20	liabilities	us-gaap:Liabilities	\$62.3M	2025-12-31	2026-03-09	10-K	0001116463-26-000016
21	operating income	us-gaap:OperatingIncomeLoss	-\$16.3M	2012-12-31	2015-03-12	10-K	0001193125-15-089338
22	interest expense	us-gaap:InterestExpense	\$172,000	2012-12-31	2015-03-12	10-K	0001193125-15-089338
23	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$4.2M	2025-12-31	2026-03-09	10-K	0001116463-26-000016
24	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$27.4M	2024-12-31	2026-03-09	10-K	0001116463-26-000016
25	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$3.8M	2024-12-31	2026-03-09	10-K	0001116463-26-000016
26	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$141.6M	2023-12-31	2026-03-09	10-K	0001116463-26-000016
27	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$5.8M	2023-12-31	2026-03-09	10-K	0001116463-26-000016
28	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$47.2M	2022-12-31	2025-03-07	10-K	0001116463-25-000010
29	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$6.8M	2022-12-31	2025-03-07	10-K	0001116463-25-000010
30	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	\$10.2M	2025-12-31	2026-03-09	10-K	0001116463-26-000016
31	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraord	\$54.6M	2025-12-31	2026-03-09	10-K	0001116463-26-000016
32	income tax	us-gaap:IncomeTaxExpenseBenefit	\$1.8M	2025-12-31	2026-03-09	10-K	0001116463-26-000016
33	current assets	us-gaap:AssetsCurrent	\$333.2M	2024-12-31	2026-03-09	10-K	0001116463-26-000016
34	current liabilities	us-gaap:LiabilitiesCurrent	\$33.5M	2024-12-31	2026-03-09	10-K	0001116463-26-000016
35	assets	us-gaap:Assets	\$482.8M	2023-12-31	2025-03-07	10-K	0001116463-25-000010
36	assets	us-gaap:Assets	\$444.2M	2022-12-31	2024-03-11	10-K	0001116463-24-000012
37	shares outstanding	dei:EntityCommonStockSharesOutstanding	69,126,173	2026-02-28	2026-03-09	10-K	0001116463-26-000016
38	shares outstanding	dei:EntityCommonStockSharesOutstanding	74,800,131	2025-02-24	2025-03-07	10-K	0001116463-25-000010